Download PDF
Erfahrungsheilkunde 2004; 53(2): 81-88
DOI: 10.1055/s-2004-819993
Originalia

Karl F. Haug Verlag, in: MVS Medizinverlage Stuttgart GmbH & Co. KG

Die Rolle regulierender Systeme bei entzündlichen Herzkrankheiten

Anwendung eines immunomodulatorischen pflanzlichen Vielstoffgemisches[*] als Zusatztherapie bei HerzkrankheitenMichal R. Zebrowski
Further Information

Publication History

Publication Date:
16 February 2004 (online)

    Permissions and Reprints

Zusammenfassung

Entzündliche Herzkrankheiten sind eine der Haupttodesursachen in den westlichen Ländern. Die hohe Komplexität des für die Regulation der Entzündungsreaktion im Organismus verantwortlichen Zytokin- und Rezeptor-Netzwerkes ist der Grund, dass bis heute keine wirksame Methode für therapeutische Eingriffe in die einzelnen Elemente entwickelt wurde. Der Fokus einer Therapie bei einer entzündlichen Herzkrankheit sollte deshalb darauf zielen, die regulative Kapazität des Organismus zu steigern, d.h. die Fähigkeit des regulatorischen Systems keine Entzündungsantwort auf den gegebenen, erhöhten Reiz zu erzeugen. Die synergistische pflanzliche Behandlung bietet eine Chance, dass die Effizienz der regulatorischen Systeme wieder hergestellt wird. Am Beispiel von PADMA 28 wird ein pflanzliches Vielstoffgemisch mit solch umfassenden, multidirektionalen Wirkungen auf den Organismus beschrieben, das diese Eigenschaften in einer einzigartigen Komposition von aktiven Substanzen aus 20 therapeutischen Kräutern nach einer überlieferten tibetischen Formel vereinigt.

Abstract

Inflammatory heart diseases are one of the main causes of death in the western society. The immeasurable complexity of the cytokine and receptor network responsible for the regulation of inflammatory reaction in organism is the reason why until today no effective methods of therapeutic intervention in its individual elements have been developed. In the case of inflammatory heart disease the focus should be placed on how to increase the “organism's regulatory capacity”, i.e. the regulatory systems' ability not to generate inflammatory response to the given enhanced stimulus. The synergetic herbal treatment offers an opportunity for the regulatory systems' efficiency to recovered. A herbal drug with this wide, multidirectional effects on the organism is PADMA 28, which owes its properties to a unique composition of active substances found in 20 therapeutic herbs selected in accordance with a Tibetan formula.

Schlüsselwörter

Regulierende Systeme - PADMA 28 - pflanzliches Vielstoffgemisch - antiinflammatorische und immunmodulatorische Zusatztherapien bei Herzkrankheiten

Keywords

Regulatory systems - PADMA 28 - herbal multi-component drug - anti-inflammatory and immune-modulatory auxiliary therapy of heart diseases

01 *PADMA 28

Literatur

  • 01 Amberger A, Maczek C, Jurgens G, Michaelis d, Schett G, Trieb K, Eberl T, Jindal s, Xu Q, Wick G. Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins.  Cell. Stress Chaperones. 1997;  2 94-103
    Google Scholar
  • 02 Amento E P, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells.  Arterioscler. Thromb.. 1991;  11 1223-1230
    Google Scholar
  • 03 Arroyo L H, Lee R T. Mechanisms of plaque rupture: mechanical and biologic interactions.  Cardiovasc. Res.. 1999;  41 369-375
    Google Scholar
  • 04 Brzosko W J. et al. . Clinical studies on Padma 28 as an immunomodulator in chronic active hepatitis.  B.J.Hepatol.. 1985;  (S 2) 1-45
    Google Scholar
  • 05 Dabrowska-Bernstein B. Padma 28 roslinny lek wspomagajacy.  Nowa Klinika. 2001;  8 370-373
    Google Scholar
  • 06 Falk E, Shah P K, Fuster V. Coronary plaque disruption.  Circulation. 1995;  92 657-671
    Google Scholar
  • 07 Ginsburg I, Sadovnik M, Sallon S, Milo-Goldzweig I, Mechoulam R, Breuer A, Gibbs D, Varani J, Roberts S, Cleator E, Singh N. PADMA 28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids.  Inflammopharmacology. 1999;  7 47-62
    Google Scholar
  • 08 Gupta S, Pablo A M, Jiang X, Wang N, Tall A R, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice.  J. Clin. Invest.. 1997;  99 2752-2761
    Google Scholar
  • 09 Gladysz A, Juszczyk J, Brzosko W. Influence of Padma 28 on patients with chronic active hepatitis B.  Phytotherapy Research. 1993;  7 244-247
    Google Scholar
  • 10 Hansson G K, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque.  Am. J. Pathol. 1989;  135 169-175
    PubMedGoogle Scholar
  • 11 Jankowski A. et al. . Padma 28 oraz inne leki I dzialania immunokorekcyjne w leczeniu nawracajacych zakazen drog oddechowych. I. Obserwacje kliniczne.  Nowiny Lekarskie. 1999;  1 61-67
    PubMedGoogle Scholar
  • 12 Jankowski A. et al. . Immunokorekcjny wlyw roslinnego leku Padma 28 u dzieci chorych na nawracajace zakazenia drog oddechowych.  Terapia. 2001;  3 33-37
    PubMedGoogle Scholar
  • 13 Karwatwska-Prokopczuk E. Srodblonek naczyniowy. Rewalacje ostatniej dekady cz II. Udzial srodblonka w stanach patologicznych.  Kard. Pol.. 1994;  2 141-144
    PubMedGoogle Scholar
  • 14 Lee T S, Yen H C, Pan C C, Chau L Y. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice.  Arterioscler. Thromb. Vasc. Biol.. 1999;  19 734-742
    PubMedGoogle Scholar
  • 15 Levine G N, Kearney J F, Vita J A. Cholesterol reduction in cardiovascular disease.  New Eng. J. Med.. 1995;  332 512-521
    CrossrefPubMedGoogle Scholar
  • 16 Libby P, Aikawa M. New Insights into plaque stabilisation by lipid lowering.  Drugs. 1998;  56 (S 1) 9-13
    PubMedGoogle Scholar
  • 17 Matzner Y, Sallon S. The effect of PADMA 28, a traditional Tibetan herbal preparation, on human neutrophil function.  J Clin Lab Immunol. 1995;  46 13-23
    PubMedGoogle Scholar
  • 18 McEvoy L M, Sun H, Tsao P S. et al. . Novel vascular molecule involved in monocyte adhesion to aortic endothelium in models of atherogenesis.  J. Exp. Med.. 1997;  185 2069-2077
    CrossrefPubMedGoogle Scholar
  • 19 Metha J L, Li D Y. Inflammation in ischemic heart disease: Response to tissue injury or a pathogenetic villain?.  Cardiovasc. Res.. 1999;  43 291-299
    CrossrefPubMedGoogle Scholar
  • 20 Natarajan R, Rosdahl J, Gonzales N, Bai W. Regulation of 12-lipoxygenase by cytokines in vascular smooth muscle cells.  Hypertension. 1997;  30 873-879
    PubMedGoogle Scholar
  • 21 Newby A C, Zaltsman A B. Fibrous cap formation or destruction - the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation.  Cardiovasc. Res.. 1999;  41 345-360
    CrossrefPubMedGoogle Scholar
  • 22 Ridker P M. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view.  Blood. Coagul. Fibrinolysis. 1999;  10 (S 1) S9-12
    PubMedGoogle Scholar
  • 23 Rohde L E, Lee R T, Rivero J, Jamacochian M, Arroyo L H, Briggs W, Rifai N, Libby P, Creager M A, Ridker P M. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis.  Arteriscler. Thromb. Vasc. Biol.. 1998;  18 1765-1770
    PubMedGoogle Scholar
  • 24 Roseenson R S, Tangney Ch C. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction.  JAMA. 1998;  279 1643-1650
    CrossrefPubMedGoogle Scholar
  • 25 Sallon S, Beer G, Rosenfeld J, Anner H, Volcoff D, Ginsberg G, Paltiel O, Berlatzky Y. The efficacy of Padma 28, a herbal preparation, in the treatment of intermittent claudication: A controlled double-blind pilot study with objective assessment of chronic occlusive arterial disease patients.  J. Vasc. Invest.. 1998;  4 129-136
    PubMedGoogle Scholar
  • 26 Samochowiec L. et al. . Effect of Padma 28 on lipid endoperoxides formation.  Herba Polonica. 1987;  33 3-7
    PubMedGoogle Scholar
  • 27 Shah P K. Role of inflammation and metalloproteinases in plaque disruption and thrombosis.  Vasc. Med.. 1998;  3 199-206
    CrossrefPubMedGoogle Scholar
  • 28 Smulski H S, Wojcicki J. Plazebokontrollierte Doppelblindstudie zur Wirkung des tibetanischen Kräuterpräparates PADMA 28 auf die Claudicatio intermittens.  Forsch Komplementärmedizin. 1994;  1 17-26
    PubMedGoogle Scholar
  • 29 Suter M, Richter Ch. Anti- and prooxidative properties of PADMA 28, a Tibetan herbal formulation.  Redox Report. 2000;  5 (1) 17-22
    PubMedGoogle Scholar
  • 30 Van der Wal A C, Becker A E. Atherosclerotic plaque rupture - pathologic basis of plaque stability and instability.  Cardiovasc. Res.. 1999;  41 334-344
    CrossrefPubMedGoogle Scholar
  • 31 Wachowicz B. Molekularne mechanizmy procesu aterogenezy.  Zagad. Biofiz. Wsp.. 1989;  1 123-134
    PubMedGoogle Scholar
  • 32 Winter K, Kharazmi A, Himmelstrup H, Drabaek H, Mehlsen J. PADMA 28, a botanical compound, decreases the oxidative burst response of monocytes and improves fibrinolysis in patients with stable intermittent claudication.  Fibrinolysis. 1994;  8 (S 2) 47-49
    PubMedGoogle Scholar
  • 33 Wojcicki J, Samochowiec L. Controlled double-blind study of Padma 28 in angina pectoris.  Herba Polonica. 1986;  33 3-7
    PubMedGoogle Scholar
  • 34 Wojcicki J, Samochowiec L, Leglecka M. et al. . Effect of Padma 28 on hyperlipidaemia and arteriosclerosis induced by hight fat diet in rabbits.  Phytother. Res.. 1988;  2 119-123
    PubMedGoogle Scholar
  • 35 Zapolska-Downar D. Miazdzyca: indukcja I modyfikadji interakcji miedzykomorkowych, rola lipoprotein.  Czynniki Ryz. 1995;  4 19-26
    PubMedGoogle Scholar
  • 36 Zebrowski A, Brzosko W J. Efficacy of PADMA 28 in treatment of patients with chronic myocarditis. Vortrag an der Scientific conference of Polish Society of Cardiology Polanica Zdroj 18.05.1990
    Google Scholar
  • 37 Zebrowski A, Krzeminska-Pakula M, Brzosko W J. Chronic Myocarditis: Pathogenic considerations and therapeutic approaches. Pesonal communication, study report 07/1986
    Google Scholar
  • 38 Zebrowski A, Zebrowski M R. Choroba zapalna serca zmiana koncepcji postepowania leczniczego w patologii kardiologicznej.  Nowa Klinika. 2002;  9 13074
    PubMedGoogle Scholar
  • 39 Zebrowski A. et al. .Treatment of chronic myocarditis with Padma 28. Lecture at Symposium of Tibetan and Western Medicine Zurich; 1986
    Google Scholar
  • 40 Zebrowski M R, Szczgiel A, Rogowski W. Mechanizmy cytokinowe miazdzycy.  Forum Kardiologow. 1998;  2-3 42-45
    PubMedGoogle Scholar

01 *PADMA 28

Korrespondenzadresse

Michal R ZebrowskiMD PhD 

Labor kardiologische Immunologie und Balneologie Kardiologische Klinik, Medizinische Universität Lodz

ul. Kniaziewicza 1/5

91-347 Lodz

Polen

Email: zebrowski@ptkardio.pl

      >